Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C

Background. Chronic hepatitis C infection is a major cause for liver failure and liver cancer and can be treated with highly effective all oral directly acting antiviral (DAA) drugs. Generic versions of these DAAs are available in India. Method. This was an open-label, single-center, prospective, no...

Full description

Saved in:
Bibliographic Details
Main Authors: L. Tang, M. Kamat, A. Shukla, M. Vora, C. Kalal, S. Kottilil, S. Shah
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Interdisciplinary Perspectives on Infectious Diseases
Online Access:http://dx.doi.org/10.1155/2018/9124604
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554846526373888
author L. Tang
M. Kamat
A. Shukla
M. Vora
C. Kalal
S. Kottilil
S. Shah
author_facet L. Tang
M. Kamat
A. Shukla
M. Vora
C. Kalal
S. Kottilil
S. Shah
author_sort L. Tang
collection DOAJ
description Background. Chronic hepatitis C infection is a major cause for liver failure and liver cancer and can be treated with highly effective all oral directly acting antiviral (DAA) drugs. Generic versions of these DAAs are available in India. Method. This was an open-label, single-center, prospective, nonrandomized observational study for the comparative safety and efficacy of generic versus brand name sofosbuvir with ribavirin therapy for chronic hepatitis C infection (all genotypes). Between December 2014 and December 2015, 66 patients received either generic sofosbuvir (400mg) or brand name SOLVALDI (400mg) with weight based ribavirin for 24 weeks in a single multispecialty hospital in Mumbai. Monitoring viral loads and safety labs was performed as per national guidelines. Results. Sustained virologic response was 72.4% versus 75.7% (p=0.78) among patients treated with generics and SOVALDI, respectively. At 4 weeks on-treatment, approximately 90% of patients from both groups had undetectable or below the lower limit of quantification. Change in hemoglobin was comparable in both groups (p=0.26). Conclusion. Generic versions of sofosbuvir reported in this study are safe and efficacious to treat hepatitis C. However, bioequivalency studies of all generic DAAs need to be performed before wider use of such drugs for the treatment of hepatitis C.
format Article
id doaj-art-833d98252dcf49bfbb479d7621e9f517
institution Kabale University
issn 1687-708X
1687-7098
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Interdisciplinary Perspectives on Infectious Diseases
spelling doaj-art-833d98252dcf49bfbb479d7621e9f5172025-02-03T05:50:24ZengWileyInterdisciplinary Perspectives on Infectious Diseases1687-708X1687-70982018-01-01201810.1155/2018/91246049124604Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis CL. Tang0M. Kamat1A. Shukla2M. Vora3C. Kalal4S. Kottilil5S. Shah6Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, Baltimore, MD, USADepartment of Hepatology, Institute of Liver Diseases, Hepato Pancreato Biliary Surgery and Transplant, Global Hospitals, Mumbai, IndiaDepartment of Hepatology, Institute of Liver Diseases, Hepato Pancreato Biliary Surgery and Transplant, Global Hospitals, Mumbai, IndiaDepartment of Hepatology, Institute of Liver Diseases, Hepato Pancreato Biliary Surgery and Transplant, Global Hospitals, Mumbai, IndiaDepartment of Hepatology, Institute of Liver Diseases, Hepato Pancreato Biliary Surgery and Transplant, Global Hospitals, Mumbai, IndiaDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland, Baltimore, MD, USADepartment of Hepatology, Institute of Liver Diseases, Hepato Pancreato Biliary Surgery and Transplant, Global Hospitals, Mumbai, IndiaBackground. Chronic hepatitis C infection is a major cause for liver failure and liver cancer and can be treated with highly effective all oral directly acting antiviral (DAA) drugs. Generic versions of these DAAs are available in India. Method. This was an open-label, single-center, prospective, nonrandomized observational study for the comparative safety and efficacy of generic versus brand name sofosbuvir with ribavirin therapy for chronic hepatitis C infection (all genotypes). Between December 2014 and December 2015, 66 patients received either generic sofosbuvir (400mg) or brand name SOLVALDI (400mg) with weight based ribavirin for 24 weeks in a single multispecialty hospital in Mumbai. Monitoring viral loads and safety labs was performed as per national guidelines. Results. Sustained virologic response was 72.4% versus 75.7% (p=0.78) among patients treated with generics and SOVALDI, respectively. At 4 weeks on-treatment, approximately 90% of patients from both groups had undetectable or below the lower limit of quantification. Change in hemoglobin was comparable in both groups (p=0.26). Conclusion. Generic versions of sofosbuvir reported in this study are safe and efficacious to treat hepatitis C. However, bioequivalency studies of all generic DAAs need to be performed before wider use of such drugs for the treatment of hepatitis C.http://dx.doi.org/10.1155/2018/9124604
spellingShingle L. Tang
M. Kamat
A. Shukla
M. Vora
C. Kalal
S. Kottilil
S. Shah
Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
Interdisciplinary Perspectives on Infectious Diseases
title Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
title_full Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
title_fullStr Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
title_full_unstemmed Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
title_short Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
title_sort comparative antiviral efficacy of generic sofosbuvir versus brand name sofosbuvir with ribavirin for the treatment of hepatitis c
url http://dx.doi.org/10.1155/2018/9124604
work_keys_str_mv AT ltang comparativeantiviralefficacyofgenericsofosbuvirversusbrandnamesofosbuvirwithribavirinforthetreatmentofhepatitisc
AT mkamat comparativeantiviralefficacyofgenericsofosbuvirversusbrandnamesofosbuvirwithribavirinforthetreatmentofhepatitisc
AT ashukla comparativeantiviralefficacyofgenericsofosbuvirversusbrandnamesofosbuvirwithribavirinforthetreatmentofhepatitisc
AT mvora comparativeantiviralefficacyofgenericsofosbuvirversusbrandnamesofosbuvirwithribavirinforthetreatmentofhepatitisc
AT ckalal comparativeantiviralefficacyofgenericsofosbuvirversusbrandnamesofosbuvirwithribavirinforthetreatmentofhepatitisc
AT skottilil comparativeantiviralefficacyofgenericsofosbuvirversusbrandnamesofosbuvirwithribavirinforthetreatmentofhepatitisc
AT sshah comparativeantiviralefficacyofgenericsofosbuvirversusbrandnamesofosbuvirwithribavirinforthetreatmentofhepatitisc